Meeder Asset Management Inc. lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 7.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 66,392 shares of the company’s stock after selling 5,363 shares during the period. Meeder Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $9,647,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of MRK. Baron Silver Stevens Financial Advisors LLC boosted its position in shares of Merck & Co., Inc. by 2.8% during the 3rd quarter. Baron Silver Stevens Financial Advisors LLC now owns 7,158 shares of the company’s stock valued at $1,040,000 after purchasing an additional 194 shares in the last quarter. Genesis Wealth Advisors LLC grew its stake in shares of Merck & Co., Inc. by 12.3% in the 3rd quarter. Genesis Wealth Advisors LLC now owns 3,761 shares of the company’s stock worth $547,000 after purchasing an additional 412 shares during the last quarter. Everest Private Wealth grew its stake in shares of Merck & Co., Inc. by 30.0% in the 3rd quarter. Everest Private Wealth now owns 2,300 shares of the company’s stock worth $334,000 after purchasing an additional 531 shares during the last quarter. Composition Wealth LLC grew its stake in shares of Merck & Co., Inc. by 2.2% in the 3rd quarter. Composition Wealth LLC now owns 101,963 shares of the company’s stock worth $14,816,000 after purchasing an additional 2,148 shares during the last quarter. Finally, Trustmark Bank Trust Department raised its holdings in shares of Merck & Co., Inc. by 5.3% in the 3rd quarter. Trustmark Bank Trust Department now owns 14,882 shares of the company’s stock worth $2,163,000 after purchasing an additional 754 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Trending Headlines about Merck & Co., Inc.
These are some of the MRK headlines that stood out recently:
- Positive Sentiment: Merck and Isomorphic Labs will combine AI-based drug discovery with Merck’s research expertise to seek small-molecule candidates for an important oncology target. The collaboration could add to Merck’s future pipeline, though it is at an early discovery stage. Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Positive Sentiment: Merck raised its quarterly dividend 3.5%, from $0.85 to $0.88 per share, signaling a modest increase in shareholder returns. Merck Announces First-Quarter 2027 Dividend
- Negative Sentiment: A separate report said MRK shares fell below their 50-day moving average following insider selling, which may add near-term technical and sentiment pressure. Merck Share Price Breaks Below 50-Day Moving Average Following Insider Selling
Merck & Co., Inc. Trading Down 3.9%
Shares of MRK opened at $137.75 on Thursday. The business’s 50-day moving average price is $145.73 and its 200 day moving average price is $129.11. The stock has a market capitalization of $339.59 billion, a P/E ratio of 142.01, a P/E/G ratio of 6.57 and a beta of 0.13. Merck & Co., Inc. has a 1-year low of $93.90 and a 1-year high of $156.92. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the previous year, the company earned $2.58 EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current year.
Merck & Co., Inc. Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.88 per share. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.85. This represents a $3.52 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, December 15th. Merck & Co., Inc.’s dividend payout ratio is presently 350.52%.
Analysts Set New Price Targets
Several analysts recently commented on MRK shares. Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday. Wolfe Research lifted their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. JPMorgan Chase & Co. upped their price target on Merck & Co., Inc. from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Finally, Guggenheim increased their price objective on Merck & Co., Inc. from $170.00 to $171.00 and gave the company a “buy” rating in a research report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $155.74.
Check Out Our Latest Stock Report on Merck & Co., Inc.
Insider Buying and Selling
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total value of $8,611,961.85. Following the completion of the sale, the executive vice president owned 112,955 shares in the company, valued at approximately $16,718,469.55. This trade represents a 34.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.17% of the stock is currently owned by company insiders.
Merck & Co., Inc. Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
